Oral phenytoin pharmacokinetics during omeprazole therapy

Br J Clin Pharmacol. 1987 Oct;24(4):543-5. doi: 10.1111/j.1365-2125.1987.tb03209.x.

Abstract

1. In a double-blind crossover study 10 healthy males received either placebo or omeprazole (40 mg day-1) for 9 days, a single dose of phenytoin (300 mg) being taken on the seventh day. 2. Omeprazole significantly increased the area under the curve (0 to 72 h) of phenytoin (mean +/- s.e. mean) from 121.6 +/- 14.0 to 151.4 +/- 13.6 micrograms ml-1 h) (P less than 0.01). 3. The peak concentration, and apparent elimination half-life of phenytoin also tended to be increased though not significantly. 4. The omeprazole-phenytoin interaction observed may be clinically important because of the low therapeutic index associated with phenytoin.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Drug Interactions
  • Half-Life
  • Humans
  • Male
  • Omeprazole / adverse effects*
  • Omeprazole / therapeutic use
  • Phenytoin / pharmacokinetics*

Substances

  • Phenytoin
  • Omeprazole